Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects (STABLE Wt Loss)

Short- and Long-term Effects of Once Weekly Semaglutide 2.4 mg on Appetite, Eating Behavior, and Psychosocial Status

This study will evaluate the effect of semaglutide on eating behavior, appetite (hunger/fullness), and food liking in the long-term, as compared to placebo. All participants will receive lifestyle modification (diet and exercise) counseling, and will be prescribed the FDA-approved weight loss medication, semaglutide, or placebo (an inactive saline solution) for 72 weeks.

Study Overview

• Status: Completed
• Conditions: Obesity
• Intervention / Treatment: Behavioral: Behavioral Treatment; Drug: Placebo; Drug: Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY]

Detailed Description

This trial consists of a single 72-week treatment period during which two studies will be conducted. Study 1 (i.e., long-term treatment trial; weeks 0-60) is a 60-week, single center, double-blinded, randomized controlled, parallel group design trial, and Study 2 (i.e., re-randomized medication withdrawal trial; weeks 60-72) is a separate, 12-week, double-blind, re-randomized medication withdrawal trial.

The long-term treatment trial (Study 1) will randomly assign (in a 3:2 semaglutide:placebo ratio) 120 subjects with a body mass index (BMI) ≥30 kg/m2, or ≥27 kg/m2 with ≥1 obesity-related co-morbidities, to 60 weeks of: 1) placebo with moderate intensity lifestyle intervention (as used in STEP 1); or 2) semaglutide 2.4 mg with the same lifestyle intervention. All subjects will receive 60 weeks of trial product, which will be up-titrated over 16 weeks in those assigned to semaglutide 2.4 mg. They will complete assessments of energy intake, appetite, food reward, mood, symptoms of disordered eating, and anthropomorphic measurements at baseline (week 0) and weeks 20, 40, and 60.

The primary aim in the initial long-term treatment trial will be to compare the long-term effect of semaglutide 2.4 mg vs placebo on ad libitum energy intake during a lunch meal at weeks 20, 40, and 60. Confirmatory secondary aims will test the effect of semaglutide 2.4 mg at weeks 20, 40 and 60 on subjective appetite ratings (both measured during a standardized breakfast in the lab and as experienced more globally over the past week), explicit food reward, as measured with the Power of Food Scale (24), and implicit food reward, as measured with the Leeds Food Preference Task (25, 26). Measures of food cravings, mood, eating disorder symptoms, and self-report measures of eating behavior will be considered supportive secondary endpoints and will provide additional evidence of the medication's safety and efficacy.

Following the completion of Study 1 at week 60, all subjects who complete a week 60 assessment and remain on drug will be enrolled in Study 2. Semaglutide-treated subjects will be re-randomized (in a 1:4 semaglutide:placebo ratio) to receive semaglutide 2.4 mg or placebo for 12 weeks. All subjects originally assigned to placebo will continue with that medication for an additional 12 weeks. Both researchers and subjects will remain blinded to subjects' original and re-randomized (or continued) treatment assignments. The goal of this re-randomized medication withdrawal period will be to compare the 80% of subjects originally assigned to semaglutide 2.4 mg who receive placebo at week 60 (semaglutide-to-placebo group) to the subjects originally randomized to placebo (continuous-placebo group) on all primary and secondary outcome measures at week 72 (after controlling for Study 1 baseline/week 0 values). All subjects will terminate trial product at cumulative week 72 and will return to clinic for a final safety visit at week 76.

Outcome assessments including ad libitum energy intake, subjective measures of appetite, food reward, eating behavior, mood, and eating disorder symptoms will occur at weeks 0, 20, 40, and 60 of Study 1 and at week 12 (72 weeks from original randomization) of the re-randomized treatment period. Measurements of body weight, waist circumference, blood pressure, pulse, and global, past-week appetite and food cravings (COEQ) also will be collected every 4 weeks throughout both treatment studies.

• Study Type: Interventional
• Enrollment (Actual): 120
• Phase: Phase 4

Contacts and Locations

Study Locations

• United States
  • Pennsylvania
    • Philadelphia, Pennsylvania, United States, 19104
      • University of Pennsylvania Center for Weight and Eating Disorders

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Men and women who report a desire to lose weight
2. Aged 18-70 years
3. Body mass index [BMI] ≥ 30 kg/m2 or BMI ≥ 27 kg/m2 with an obesity-related comorbidity (e.g., treated or untreated hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease)

4. Eligible female patients will be:

   • non-pregnant, evidenced by a negative urine pregnancy test
   • non-lactating
   • surgically sterile or postmenopausal, or they will agree to continue to use an accepted method of birth control during the study

5. Subjects must

   • Plan to remain in the Philadelphia area for the next 1.5 years.
   • Ability to provide informed consent before any trial-related activities.

Exclusion Criteria:

1. A diagnosis of type I or II diabetes
2. Hemoglobin A1c (HbA1c) > 6.5%
3. Uncontrolled hypertension (blood pressure ≥ 160/100 mm Hg)
4. Clinically significant hepatic (i.e., liver fibrosis, cirrhosis or confirmed NASH) or renal disease
5. Uncontrolled thyroid disease
6. Experienced a cardiovascular event (e.g., stroke, myocardial infarction) in the last 6 months, congestive heart failure, or heart block greater than first degree
7. A history of acute pancreatitis in the last 6 months
8. Any history of chronic pancreatitis
9. A history of malignancy (other than non-melanoma skin cancer) within the last 5 years
10. A personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2
11. A self-reported change in body weight >5kg (11 lbs) within 90 days before screening
12. Used within the last 6 months medications known to produce weight loss/gain (e.g., medications approved for weight loss, oral steroids, antipsychotic medications) or any GLP-1 receptor agonist.
13. Known or suspected allergy or hypersensitivity to trial medication(s), excipients, or related products
14. The receipt of any investigational drug within 6 months prior to this trial
15. Applicants with current severe major depressive disorder (BDI-II score ≥ 29 or Patient Health Questionnaire-9 [PHQ-9] score > 15) or severe anxiety disorder
16. Applicants with current, active suicidal ideation, and/or a suicide attempt within the past year (such individuals will be referred for psychiatric treatment if they have not previously received it).
17. Any severity of psychotic or bipolar disorder
18. Bulimia nervosa diagnosis within the past 5 years
19. Self-reported alcohol or substance abuse within the past 6 months, including at-risk drinking (current consumption of ≥ 14 alcoholic drinks per week)
20. History of (or plans to receive in the next 1.5 years) bariatric surgery or a weight loss device. (However, the following will be allowed: liposuction or abdominoplasty > 1 year before screening, laparoscopic banding if removed > 1 year before screening, intragastric balloon or aspire assist if removed > 1 year before screening.)
21. Inability to walk 5 blocks or more (comfortably) or engage in another form of aerobic activity.
22. Women who are nursing, pregnant, or planning to become pregnant in the next 1.5 years or are not using adequate contraceptive measures
23. Previous participation in this trial (e.g., randomized but failed to participate)
24. Changes to any chronic medication (type or dosage) within the past 3 months.
25. Food allergy or dietary preference that would prevent the individual from consuming the standard breakfast or ad libitum lunch.

1. To be eligible to participate in the re-randomized treatment period from weeks 60 to 72, subjects must also:

• complete a week 60 assessment
• be classified as "on drug" as at the week 60 assessment and report taking at least one dose of trial product within the past 2 weeks

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Behavioral Treatment + Placebo (weeks 0-60) // Continuous Placebo (weeks 60-72); Behavioral treatment (lifestyle modification counseling for weight loss) plus placebo from weeks 0 - 60. At week 60, all placebo-treated participants were (sham) re-randomized to continue placebo for an additional 12 weeks (i.e., continuous placebo group).	Behavioral: Behavioral Treatment; All participants, regardless of medication assignment, will receive the same 60-week behavioral weight loss program. Brief (15-minute), individual lifestyle counseling sessions will be delivered by a psychologist, behavioral health counselor, or registered dietitian (or other trained health care provider) at weeks 0 (i.e., baseline/randomization), 2, 4 and every fourth week from week 4 to week 60 (17 sessions) of Study 1. Subjects will be instructed to consume a self-selected diet of 1200-1500 kcal/day (for those who weigh < 250 lb) or 1500-1800 kcal/day (for those who weigh ≥250 lb). They will be instructed to engage in low-to-moderate intensity physical activity (e.g., walking), gradually building to a goal of ≥150 minutes per week (spread across 5 days) by week 40. They will be instructed to use calorie counting and self-monitoring to meet their goals.; Other Names: Lifestyle modification; Behavioral weight loss; Lifestyle intervention; Drug: Placebo; An inactive saline solution administered via subcutaneous injection; Other Names: Placebo for medication
Active Comparator: Behavioral Treatment + Medication (weeks 0-60) // Switched to Placebo (weeks 60-72); Behavioral treatment (lifestyle modification counseling for weight loss) plus semaglutide from weeks 0 to week 60. At week 60, semaglutide-treated participants were re-randomized 4:1 to either switch to placebo or continue semaglutide for an additional 12 weeks (weeks 60 - 72). By re-allocating a small number of subjects to semaglutide-to-semaglutide at week 60, both researchers and subjects remain blinded to medication condition during the re-randomized treatment period. However, the semaglutide-to-semaglutide group was not intended to be subject to statistical analysis. Therefore the week 72 results for this group represent those of the semaglutide-to-placebo group who took semaglutide for 60 weeks and then placebo for the last 12 weeks.	Behavioral: Behavioral Treatment; All participants, regardless of medication assignment, will receive the same 60-week behavioral weight loss program. Brief (15-minute), individual lifestyle counseling sessions will be delivered by a psychologist, behavioral health counselor, or registered dietitian (or other trained health care provider) at weeks 0 (i.e., baseline/randomization), 2, 4 and every fourth week from week 4 to week 60 (17 sessions) of Study 1. Subjects will be instructed to consume a self-selected diet of 1200-1500 kcal/day (for those who weigh < 250 lb) or 1500-1800 kcal/day (for those who weigh ≥250 lb). They will be instructed to engage in low-to-moderate intensity physical activity (e.g., walking), gradually building to a goal of ≥150 minutes per week (spread across 5 days) by week 40. They will be instructed to use calorie counting and self-monitoring to meet their goals.; Other Names: Lifestyle modification; Behavioral weight loss; Lifestyle intervention; Drug: Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY]; Semaglutide 2.4 mg is a once weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist that has been FDA approved for weight loss; Other Names: Wegovy

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Study 1 Ad Libitum Energy Intake (kcal) During a Buffet Lunch Meal (4 Hrs After Standardized Breakfast)	Primary outcome (Study 1)	S1: Change from baseline to weeks 20, 40, and 60
Study 2 Ad Libitum Energy Intake (kcal) During a Buffet Lunch Meal (4 Hrs After Standardized Breakfast)	Primary outcome (Study 2)	S2: Endpoint comparison at week 72

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Study 1 Laboratory-based Appetite Measured as a Composite of Visual Analogue Scale Ratings (Hunger, Fullness, Satiety, Prospective Consumption) When Fasting	Secondary confirmatory outcome (Study 1): This is a single value calculated by averaging 100-mm VAS ratings for hunger (reversed), fullness, satiety, and prospective food consumption (reversed) as measured when fasting prior to eating a standardized breakfast. Score range 0-100 mm. Higher values indicate greater suppression (i.e., less appetite).	S1: Change from baseline to weeks 20, 40, and 60
Study 1 Laboratory-based Appetite Measured as a Composite of Visual Analogue Scale Ratings (Hunger, Fullness, Satiety, Prospective Consumption) After Eating (Area Under the Curve)	Secondary confirmatory outcome (Study 1): This is a single value calculated by averaging 100-mm VAS ratings for hunger (reversed), fullness, satiety, and prospective food consumption (reversed) as measured every 30 minutes in the 4 hours after eating a standardized breakfast. Post-prandial scores were combined into a single area under the curve value using the trapezoidal method. Possible area range: 0 - 24,000. Higher values indicate greater suppression (i.e., less appetite).	S1: Change from baseline to weeks 20, 40, and 60
Study 1 Past-week Hunger as Measured Using the Control of Eating Questionnaire (COEQ)	Secondary confirmatory outcome (Study 1): Visual analogue scale rating of hunger during the past week (Control of Eating Questionnaire; COEQ). Score range 0-100 mm. Higher scores indicate greater hunger.	S1: Change from baseline to weeks 20, 40, and 60
Study 1 Past-week Fullness After Meals as Measured Using the Control of Eating Questionnaire (COEQ)	Secondary confirmatory outcome (Study 1): Visual analogue scale rating of fullness after meals during the past week (Control of Eating Questionnaire; COEQ). Score range 0-100 mm. Higher scores indicate greater fullness after meals.	S1: Change from baseline to weeks 20, 40, and 60
Study 1 Past-week Food Preoccupation as Measured Using the Control of Eating Questionnaire (COEQ)	Secondary confirmatory outcome (Study 1): Visual analogue scale rating of food preoccupation during the past week (Control of Eating Questionnaire; COEQ). Score range 0-100 mm. Higher scores indicate greater food preoccupation.	S1: Change from baseline to weeks 20, 40, and 60
Study 1 Explicit Responsiveness to the Food Environment (Power of Food Scale 15-item Version)	Secondary confirmatory outcome (Study 1): Explicit responsiveness to the food environment measured by the summary score of the Power of Food Scale (15-item version). Score range 1-5. Higher scores indicate greater responsiveness to the food environment.	S1: Change from baseline to weeks 20, 40, and 60
Study 1 Implicit Food Wanting of High-fat, Savory Foods Measured Using the Leeds Food Preference Task	Secondary confirmatory outcome (Study 1): Implicit food wanting of high-fat, savory foods measured using the Leeds Food Preference Task. Scores range from -100 to +100 with higher scores indicating a greater implicit wanting of high-fat savory foods.	S1: Change from baseline to weeks 20, 40, and 60
Study 2 Laboratory-based Appetite Measured as a Composite of Visual Analogue Scale Ratings (Hunger, Fullness, Satiety, Prospective Consumption) When Fasting	Secondary confirmatory outcome (Study 2): This is a single value calculated by averaging 100-mm VAS ratings for hunger (reversed), fullness, satiety, and prospective food consumption (reversed) as measured when fasting prior to eating a standardized breakfast. Score range 0-100 mm. Higher values indicate greater suppression (i.e., less appetite).	S2: Week 72 endpoint controlling for S1 baseline
Study 2 Laboratory-based Appetite Measured as a Composite of Visual Analogue Scale Ratings (Hunger, Fullness, Satiety, Prospective Consumption) After Eating (Area Under the Curve)	Secondary confirmatory outcome (Study 2): This is a single value calculated by averaging 100-mm VAS ratings for hunger (reversed), fullness, satiety, and prospective food consumption (reversed) as measured every 30 minutes in the 4 hours after eating a standardized breakfast. Post-prandial scores were combined into a single area under the curve value using the trapezoidal method. Possible area range: 0 - 24,000. Higher values indicate greater suppression (i.e., less appetite).	S2: Week 72 endpoint controlling for S1 baseline
Study 2 Past-week Hunger as Measured Using the Control of Eating Questionnaire (COEQ)	Secondary confirmatory outcome (Study 2): Visual analogue scale rating of hunger during the past week (Control of Eating Questionnaire; COEQ). Score range 0-100 mm. Higher scores indicate greater hunger.	S2: Week 72 endpoint controlling for S1 baseline
Study 2 Past-week Fullness After Meals as Measured Using the Control of Eating Questionnaire (COEQ)	Secondary confirmatory outcome (Study 2): Visual analogue scale rating of fullness after meals during the past week (Control of Eating Questionnaire; COEQ). Score range 0-100 mm. Higher scores indicate greater fullness after meals.	S2: Week 72 endpoint controlling for S1 baseline
Study 2 Past-week Food Preoccupation as Measured Using the Control of Eating Questionnaire (COEQ)	Secondary confirmatory outcome (Study 2): Visual analogue scale rating of food preoccupation during the past week (Control of Eating Questionnaire; COEQ). Score range 0-100 mm. Higher scores indicate greater food preoccupation.	S2: Week 72 endpoint controlling for S1 baseline
Study 2 Explicit Responsiveness to the Food Environment (Power of Food Scale 15-item Version)	Secondary confirmatory outcome (Study 2): Explicit responsiveness to the food environment measured by the summary score of the Power of Food Scale (15-item version). Score range 1-5. Higher scores indicate greater responsiveness to the food environment.	S2: Week 72 endpoint controlling for S1 baseline
Study 2 Implicit Food Wanting of High-fat, Savory Foods Measured Using the Leeds Food Preference Task	Secondary confirmatory outcome (Study 2): Implicit food wanting of high-fat, savory foods measured using the Leeds Food Preference Task. Scores range from -100 to +100 with higher scores indicating a greater implicit wanting of high-fat savory foods.	S2: Week 72 endpoint controlling for S1 baseline

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Study 1 Body Weight (kg)	Supportive secondary outcome (Study 1): Body weight change (kg)	S1: Change from baseline to weeks 20, 40, and 60
Study 1 Craving Control Over the Past Week as Measured by the COEQ	Supportive secondary outcome (Study 1): Composite (mean) of visual analogue scale ratings for craving control (Control of Eating Questionnaire; COEQ). Score range 0-100 mm. Higher scores indicate greater ability to control food cravings.	S1: Change from baseline to weeks 20, 40, and 60
Study 1 Craving for Savory Over the Past Week as Measured by the COEQ	Supportive secondary outcome (Study 1): Composite (mean) of visual analogue scale ratings for craving for savory foods (Control of Eating Questionnaire; COEQ). Score range 0-100 mm. Higher scores indicate stronger/more frequent cravings for savory foods.	S1: Change from baseline to weeks 20, 40, and 60
Study 1 Craving for Sweet Over the Past Week as Measured by the COEQ	Supportive secondary outcome (Study 1): Composite (mean) of visual analogue scale ratings for craving for sweet foods (Control of Eating Questionnaire; COEQ). Score range 0-100 mm. Higher scores indicate stronger/more frequent cravings for sweet foods.	S1: Change from baseline to weeks 20, 40, and 60
Study 1 Food Cravings as Measured by the General Food Cravings Questionnaire - Trait	Supportive secondary outcome (Study 1): Food cravings as measured by the General Food Cravings Questionnaire - Trait (G-FCQ-T 21-item). Score range 21-126, higher scores indicate more/stronger food cravings.	S1: Change from baseline to weeks 20, 40, and 60
Study 1 Explicit Liking of High-fat Savory Foods (LFPT)	Supportive secondary outcome (Study 1) Explicit liking of high-fat savory foods as measured on 100-mm VAS scales (mean of high-fat savory items) during the Leeds Food Preference Task. Score range 0 - 100 mm with higher scores indicating greater liking of high-fat savory foods.	S1: Change from baseline to weeks 20, 40, and 60
Study 1 Cognitive Restraint (Eating Inventory)	Supportive secondary outcome (Study 1): Eating behavior - cognitive restraint subscale of the Eating Inventory (EI). Score range 0-21, higher=more dietary restraint.	S1: Change from baseline to weeks 20, 40, and 60
Study 1 Disinhibition (Eating Inventory)	Supportive secondary outcome (Study 1): Eating behavior - disinhibition subscale of the Eating Inventory. Score range 0-16, higher=more disinhibition.	S1: Change from baseline to weeks 20, 40, and 60
Study 1 Weight-related Self-efficacy	Supportive secondary outcome (Study 1) Mean score on the Weight-related self-efficacy (WEL-short form). Sum of 8 items, score range 0-80, higher scores indicate greater weight-related self-efficacy.	S1: Change from baseline to weeks 20, 40, and 60
Study 1 Mood as Assessed Using the PHQ-9	Supportive secondary outcome (Study 1): Depressed mood as assessed using the PHQ-9. Score range 0 - 27; higher scores indicate more symptoms of depressed mood.	S1: Change from baseline to weeks 20, 40, and 60
Study 1 Clinician-rated Binge Eating Frequency (Sum of Objective and Subjective Binge Eating Frequency)	Supportive secondary outcome (Study 1): Clinician-rated binge eating frequency (sum of objective and subjective binge eating frequency) in the past 12 weeks as assessed by the Eating Disorder Examination (EDE). Score is the count of binge episodes, range ≥0, more episodes indicates more frequent binge eating in the past 12 weeks.	S1: Change from baseline to weeks 20, 40, and 60
Study 1 Self-reported Loss-of-control Eating (Loss of Control Eating Scale)	Supportive secondary outcome (Study 1): Self-reported loss-of-control eating as measured by the Loss of Control Eating Scale (LOCES). Mean score range 1-5; higher scores indicate greater/more frequent loss of control over eating.	S1: Change from baseline to weeks 20, 40, and 60
Study 1 Food Addiction Symptoms Measured by Yale Food Addiction Scale	Exploratory outcome (Study 1): Food addiction symptoms measured by Yale Food Addiction Scale (YFAS). Symptom number range 0-11, higher scores indicate more food addiction symptoms	S1: Change from baseline to weeks 20, 40, and 60
Study 1 Drive for Thinness (Eating Disorder Inventory [EDI])	Supportive secondary outcome (Study 1): Study 1 Drive for thinness as measured by the Eating Disorder Inventory (EDI). Score range 0-28; higher scores indicate greater drive for thinness.	Change from baseline to weeks 20, 40, and 60
Study 1 Ratings of Nausea When Fasting	Exploratory outcome (Study 1): Ratings of nausea using 100 mm visual analogue scales when fasting in the laboratory prior to consuming the standard breakfast meal. Score range 0-100 mm; higher scores indicate greater nausea.	S1: Change from baseline to weeks 20, 40, and 60
Study 1 Ratings of Food Palatability	Exploratory outcome (Study 1): Ratings of food palatability using 100 mm visual analogue scales during a laboratory test meal. Score range 0-100 mm; higher scores indicate higher liking of the food taste.	S1: Change from baseline to weeks 20, 40, and 60
Study 1 Body Image Dissatisfaction (Body Satisfaction Scale)	Exploratory outcome (Study 1): Body image dissatisfaction (Body Satisfaction Scale). Mean of 13 items, score range 1-7, higher scores indicate greater body part dissatisfaction.	S1: Change from baseline to weeks 20, 40, and 60
Study 1 Weight-related Self Stigmatization	Exploratory outcome (Study 1): Weight-related self stigmatization by the Weight Bias Internalization Scale. Mean of 11 items; score range 1-7; higher scores indicate greater weight-related self-stigmatization.	S1: Change from baseline to weeks 20, 40, and 60
Study 2 Body Weight (kg)	Supportive secondary outcome (Study 2): Body weight (kg) at week 72	S2: Week 72 endpoint controlling for S1 baseline

Collaborators and Investigators

• Sponsor: University of Pennsylvania
• Collaborators: Novo Nordisk A/S

Publications and helpful links

General Publications

• Gordon K, Matthews A, Zeller MH, Lin J. Practical guidelines for eating disorder risk mitigation in patients undergoing obesity treatment for the pediatric provider. Curr Opin Pediatr. 2024 Aug 1;36(4):367-374. doi: 10.1097/MOP.0000000000001356. Epub 2024 Apr 5.
• Tronieri JS, Allison KC, DeRouen K, Amaro A, Collins KG, Roy A, Watts S, Ananna T, Wadden TA. Short- and long-term effects of semaglutide 2.4 mg on energy intake, appetite, and food reward: a 60-week, double-blind randomized controlled trial. Am J Clin Nutr. 2026 Jun 20:101403. doi: 10.1016/j.ajcnut.2026.101403. Online ahead of print.

Study record dates

Study Major Dates

• Study Start (Actual): July 26, 2022
• Primary Completion (Actual): May 12, 2025
• Study Completion (Actual): May 12, 2025

Study Registration Dates

• First Submitted: September 14, 2022
• First Submitted That Met QC Criteria: September 19, 2022
• First Posted (Actual): September 21, 2022

Study Record Updates

• Last Update Posted (Actual): August 3, 2026
• Last Update Submitted That Met QC Criteria: July 30, 2026
• Last Verified: July 1, 2026

More Information

Terms related to this study

• Keywords: Obesity; exercise; overweight; medication; Semaglutide; weight loss; diet; Body weight; lifestyle modification; Body Weight Changes; Appetitive Behavior
• Additional Relevant MeSH Terms: Nutrition Disorders; Overnutrition; Pathological Conditions, Signs and Symptoms; Behavior; Nutritional and Metabolic Diseases; Signs and Symptoms; Behavior, Animal; Overweight; Obesity; Weight Loss; Body Weight; Body Weight Changes; Motor Activity; Appetitive Behavior; Pharmaceutical Preparations; Investigative Techniques; Technology, Pharmaceutical; Psychotherapy; Behavioral Disciplines and Activities; Dosage Forms; semaglutide; Behavior Therapy
• Other Study ID Numbers: 850370

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No